Characteristics of the study population (n=703) at the end of the follow-up period (31 July 2015)
| New cases of diabetes (n=132) | No diabetes (n=571) | P value | |
| Age at diabetes diagnosis or the end of study (years); median (Q1–Q3) | 55 (50–61) | 56 (53–61) | <0.001 |
| CD4 count at the end of follow-up (cells/mm3); median (Q1–Q3) | 395 (260–615) | 530 (350–720) | <0.001 |
| Time from antiretroviral therapy initiation to develop diabetes or the end of study (years); median (Q1–Q3) | 7.9 (5.6–10.6) | 9.3 (5.7–13.5) | 0.005 |
| Time from HIV diagnosis to develop diabetes or the end of study (years); median (Q1–Q3) | 9.0 (6.2–11.6) | 11.8 (7.8–16.2) | <0.001 |
| Proportion of follow-up time with plasma viral load ≥500 copies/mL; median (Q1–Q3) | 16% (6–36) | 7% (2–25) | <0.001 |
Q1–Q3, 25th and 75th percentile.